Lecturers 2019

Marianne Alanko

Niklas Björkström
Niklas Björkström is a resident physician in clinical microbiology at Karolinska University hospital, Huddinge, Sweden, and an Associate Professor in Immunology. He leads a research team within Center for Infectious Medicine at ANA Futura - a newly built research facility at Karolinska Institutet. The main focus of the research group is to understand more about the biology behind tissue-resident natural killer (NK) cells. The previous hypothesis that NK cells mainly recirculate from tissue to blood has been re-evaluated in recent years, and it is now known that NK cells are much more tissue-specific than what was earlier believed. One part of the groups research is to gain better insight into the function and course of development of uterine resident NK cells, by detailed characteriztion of their cell surface expression of killer immunoglobulin-like receptors (KIR). Another interest of the group is resident NK cells in the liver. The goal is to understand how these cells might be involved in the pathogenesis of different liver diseases, such as primary sclerosing cholangitis (PSC), steatohepatitis (NASH), and hepatitis virus infections (HBV, HCV, HDV), all inflammatory conditions associated with an increased risk of tumor development. The group is specialized in advanced 30-parameter flow cytometry and microscopy, and use these techniques for phenotypic and functional studies of NK cells in health and disease. Recently they have also developed a sensitive method for isolating and analyzing immune cells from the bile duct tree, which so far is a relatively unexplored organ from an immunological point of view.

Maria Buti
Maria Buti earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain. She is currently Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. Dr Butí has worked in viral hepatitis for the 30 years, particularly in diagnosis and therapy of hepatitis B and C. She has been published widely more than 400 manuscripts in peer review journals in the field of viral hepatitis and contributions to books. She is in the Editorial Board of Journal of Hepatology and Liver International. She is part of the expert Committee in the Spanish National Plan against Hepatitis C. She is very active in clinical trials and has been principal investigator in many studies.
She was president of the Spanish Association for the Study of Liver Diseases, and an active member of the EASL, and the AASLD and various professional societies.
Christina Carlander

Olav Dalgard
Olav Dalgard is a professor of infectious diseases at Akershus University Hospital in Norway. His main research interest is hepatitis C infection in people who inject drugs focusing on natural history of the disease and delivery of care. He is currently studying new models of care for HCV among PWID and reinfection after successful HCV treatment. He has been chairing the committee who writes HCV and HBV treatment guidelines in Norway and is a member of the work group writing HCV guidelines for the European Association for the study of Liver Disease (EASL).

Susanne Dam Poulsen
Susanne Dam Poulsen (given name Susanne Dam Nielsen), Copenhagen, Denmark.
Susanne Dam Poulsen is professor of infectious diseases at Department of Infectious Diseases, University of Copenhagen Rigshospitalet. She has worked with HIV, inflammation, and immunology for 25 years, and the last decade she has worked with HIV-related comorbidities. She now leads a research team that studies HIV comorbidities, and she is the PI of the Copenhagen Comorbidity in HIV (COCOMO) study.
John Dillon
Lucy Dorrell

Jacob Estes
Dr. Estes obtained his Ph.D. in Immunology and HIV Pathogenesis in 2003 from Brigham Young University working in the laboratory of Dr. Gregory Burton. From 2003 to 2007, he was a postdoctoral fellow in the laboratory of Dr. Ashley Haase in the Department of Microbiology at the University of Minnesota focusing on the in vivo immunopathology of HIV/SIV infections. Following his postdoctoral training, Dr. Estes joined the AIDS and Cancer Virus Program at the Frederick National Laboratory for Cancer Research led by Dr. Jeff Lifson, and was a Senior Principal Investigator of the Retroviral Immunopathology Section and Head of the Tissue Analysis Core. Dr. Estes was appointed an Adjunct Professor in the School of Health and Biomedical Sciences in the College of Science, Engineering and Health at RMIT University in Melbourne, Australia in 2017. Later in 2017, Dr. Estes accepted a dual appointment as Professor within the Vaccine and Gene Therapy Institute (VGTI) and Chief of the Division of Pathobiology & Immunology at the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU). The central focus of Dr. Estes’s research seeks to understand how HIV/SIV-driven immune response dysregulation leads to tissue pathology, disease progression, and viral persistence with the goal to develop and test effective therapeutic strategies that prevent disease, restore immune function and impact viral reservoir persistence.

Jan Gerstoft
Jan Gerstoft is professor of clinical virology at the University of Copenhagen, Denmark. He works at the department of infectious diseases at Rigshospitalet where he is heading the outpatient clinic that primarily takes care of HIV and hepatitis patients. His research has mainly been focused on HIV, since he described the first European AIDS patients in 1981. His research has involved clinical trials of antiviral agents, resistance and cohort studies of co-morbidities. The research has been published in more than 400 papers often in high impact journals.
Marianne Jansson

Anna Jerkeman
Senior consultant at the Department of Infectious Diseases, Skane University Hospital, Malmö.
Area of research: Hepatitis C in people who inject drugs. Have conducted clinical trials on hepatitis C treatment in the OST (opiate substitution treatment) and NEP (needle exchange program) setting.

Terese L Katzenstein
Terese L Katzenstein is chief physician at the Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet. Terese Katzenstein has been involved in HIV treatment and research for more than 20 years. Terese Katzenstein has a special interest in women living with HIV and their children. Both her PhD and MDSc theses were based on studies within the field of clinical virology. Dr. Katzenstein has authored/co-authored more than 140 publications, primarily on HIV related issues. Current research activities includes studies on bone health and treatment optimization and monitoring in Tanzania.
Martin Kåberg

Anne-Geneviève Marcelin
Anne-Geneviève Marcelin is Professor of Medicine at Sorbonne Université in Paris, France and clinical virologist at the Pitié-Salpêtrière Hospital. She’s head of a research team (Inserm UMR 1136) dedicated to Therapeutic strategies for HIV infection and associated viral diseases.
Pr Anne-Geneviève Marcelin research interests include HIV mechanisms of resistance to antiretrovirals, new therapy strategies for HIV treatment and new antiretroviral agents. She serves as a member of Agence Nationale de Recherches sur le SIDA et les hepatites virales (ANRS), in the French AC43 resistance group (www.hivfrenchresistance.org) and is chair of the ANRS Next generation sequencing network.
She’s member of the WHO Steering Group that provides high level guidance and supports in developing and implementing WHO global HIV drug resistance prevention, surveillance and response strategy and is co-chair of the WHO Working Group 3, on Research and Innovation.

Lynne M Mofenson
Dr. Mofenson is an infectious disease specialist and Board-Certified pediatrician who has spent her career doing research on prevention and treatment of pediatric and maternal HIV infection. Following several years in private practice of infectious diseases and pediatrics, where she took care of some of the first AIDS patients in Massachusetts in the early 1980’s, she joined the Massachusetts Department of Public Health as Assistant Commissioner for Division of Communicable Disease Control in 1985. In 1989, she moved to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), here she spent the next 26 years, first as Associate Branch Chief for Clinical Research in the Pediatric, Adolescent and Maternal AIDS Branch and then as Branch Chief in the Maternal and Pediatric Infectious Disease Branch from 2000-2014. At NICHD, she was responsible for program planning and development and scientific direction of research, epidemiologic studies, and clinical trials in domestic and international pediatric, adolescent and maternal HIV infection, led many of the key clinical trials on prevention of mother to child transmission and pediatric and maternal treatment. She currently serves as Senior HIV Technical Advisor to the Research Program at the Elizabeth Glaser Pediatric AIDS Foundation, where she is assisting in evaluating implementation of many of the interventions on treatment and prevention that she helped to design while at NIH.
Beatriz Mothe
Chloe Orkin
Jannick Prentø

Ronald Swanstrom
Ronald Swanstrom is Professor of Biochemistry and Biophysics and Director of the UNC Center For AIDS Research, University of North Carolina at Chapel Hill, USA. He studies HIV-1 evolution and pathogenesis, especially as it pertains to viral entry and cell tropism. Other interests include the viral protease and protease inhibitors, and viral RNA splicing. A recent focus has been the study of when HIV-1 enters the long-lived viral reservoir that persists during suppressive antiviral therapy.
Johannes Vermehren
Sharon Walmsley

Ola Weiland
Ola Weiland has a present position as senior professor in Infectious Diseases at Karolinska Institutet at the Department of Medicine, Karolinska Institutet, and a senior consultancy at Karolinska University Hospital Huddinge, Stockholm, Sweden. Professor Weiland has received his medical degree from Karolinska Institute in 1972 and achieved board certification as a Specialist in Infectious Diseases in 1977. His research on hepatitis A, B and non-A, non-B virus gained him a PhD at the Karolinska Institute in 1981. Professor Weiland is a member of the European and American Association for Study of the Liver, the Infectious Disease Society of America, and the Swedish Societies for Medicine, Infectious Diseases, and Tropical Medicine. He is also president of the Society of the Scandinavian Journal of Infectious Diseases and is on the board of the Scandinavian Journal of Gastroenterology. He has published over 250 original articles, in addition to 40 reviews or book chapters. His main research interests covers the mechanisms of action, immunological response to, clinical development, and evaluation of antiviral therapy for chronic hepatitis B and C.